ABSTRACT
Objectives: To
analyze whether vessel density or nerve fiber layer thicknes (structural
properties) obtained by optical
coherence tomography angiography (OCT-A) could differentiate between healthy
controls and patients with ocular hypertension or mild, moderate and severe
glaucoma. In addition, to determine if vessel density or nerve fiber layer
thickness is most helpful in detecting early glaucomatous damage.
Methods: In
this retrospective study, we selected 69 healthy controls, 36 patients with
ocular hypertension, and 91 with primary open-angle glaucoma (54 mild, 25
moderate, and 12 severe). One eye was randomly selected per patient. Patients
were excluded if they were < 18 years, had secondary glaucoma, OCT-A signal
strength index < 40, refractive errors > ± 5 D, vision worse than 20/40, or only one
functional eye. Collected
data included: age, ethnicity, gender, family history of
glaucoma, intraocular
pressure, visual fields, cup/disc ratio, and OCT-A macular and optic nerve head
scanning parameters.
Results: Whole image optic nerve head and macular vessel
density both decreased as the glaucoma progressed, from ocular hypertension to
severe stage, 56.7% to 43.1% and 49.0% to 43.4%, respectively (p<0.01).
Similarly, average nerve fiber layer thickness decreased from, 92.0μm to 60.1μm
(p<0.01) in patients with ocular hypertension to those with severe glaucoma.
Both
structural properties and vessel density were equally effective at determining
glaucoma stage. Between healthy controls and patients with ocular hypertension, we noticed structural property
differences, but no vessel density differences.
Conclusion: Both
optic nerve head and macular vessel density and structural properties assessed
by OCT-A may provide an objective measure of glaucomatous damage in the eye. In
addition, we have found that structural damage may occur before vessel density
damage in ocular hypertension.
Keywords: primary open
angle glaucoma, optical coherence tomography angiography,
ocular hypertension.
RMS April 2022; 29 (2): 10.12816/0061165
INTRODUCTION
Glaucoma is the second most common cause
of blindness worldwide and primary open-angle glaucoma (POAG) is the most
prevalent form(1).
The
latter is a chronic, progressive optic neuropathy with a characteristic atrophy
of the optic nerve, loss of retinal ganglion cells and their axons, and an open
anterior chamber angle with or
without elevated intraocular pressure (IOP)(1). Currently,
POAG is diagnosed and classified based on visual field (VF) testing using
standard automated perimetry(1). However, the VF test is
subjective, time consuming, poor at reproducibility, and often is unable to
diagnose early glaucoma damage or provide reliable evidence of progression of
the disease(2). Due to the limitations of VF
testing and the frequent variability of IOP measurements, ophthalmologists
cannot always determine whether a patient with ocular hypertension will
progress to glaucoma based on VF or IOP alone(1,3). Therefore, there exists a need
for new, objective, and reliable methods to both diagnose glaucoma and glaucoma
progression early in order to start appropriate treatment.
In recent years, optic coherence
tomography (OCT) has provided a non-invasive way to measure macular ganglion
cell complex (mGCC) and retinal nerve fiber layer (RNFL) thickness and has been
shown to notice glaucomatous damage before VF changes are noted by up to eight
years and to determine the glaucoma stage(4,5). Since 2014, OCT-A is a new,
non-invasive modality that can in addition visualize the microvasculature of
the optic nerve head (ONH), retina, choroid, and peripapillary region and
provide reproducible and quantitative vessel density measurements that can help
in the management of POAG(6). While previous studies have
shown a decrease in vessel density in glaucoma, it is not well known if OCT-A
is also effective in detecting early glaucoma damage in ocular hypertension or
progression in patients diagnosed with glaucoma(6).
Therefore, this retrospective study was
designed to determine if structural or vessel properties measured by OCT-A
could differentiate between healthy controls, and those diagnosed with ocular
hypertension or POAG (mild, moderate, and severe), and which of these two
methods is more helpful in detecting early glaucomatous damage.
METHODS
Study Design
In this retrospective, case-control
study, we reviewed the electronic medical records of all consecutive patients
diagnosed with ocular hypertension or POAG who underwent OCT-A at the
University of Texas Southwestern (UTSW) Medical Center Eye Clinic from March
2016 to June 2017. A cohort of
healthy individuals was also selected. A list of all patients undergoing OCT-A
was maintained by clinical staff at the UTSW tertiary care eye clinic. Approval
by the Institutional Review Board of UTSW was obtained, and we followed the
tenets of the United States Health Insurance Portability and Accountability Act
of 1996 (HIPAA) and the Declaration of Helsinki for research involving human
subjects.
Selection of
Patients
All patients who had reliable OCT-A and
VF test results and were above 18 years old were included. Patients were
excluded if they had secondary glaucoma, narrow angle-closure glaucoma, retinal
diseases (diabetic retinopathy, hypertensive retinopathy), history of
intraocular surgery other than uncomplicated cataract or glaucoma surgery,
uveitis, ocular trauma, Parkinson disease, Alzheimer disease, stroke, VF
fixation loss >33%, VF false-positive or false-negative errors >33%,
refractive errors greater than ± 5 diopters or greater than ± 3 cylinder,
corrected visual acuity worse than 20/40, or only one functional eye.
Unreliable OCT-A images were defined as images with an SSI <40, motion
artifacts, segmentation errors, or poor clarity.
Patients were divided into 5 separate
groups: healthy patients without
glaucoma (controls), ocular hypertension, and POAG (mild, moderate, and
severe). Healthy controls had IOP less than 21 mmHg bilaterally with no history
of elevated IOP, intact neuroretinal rims and retinal nerve fiber layer, no VF
defects, and were not on any anti-glaucoma medications. Patients with ocular
hypertension had no VF defects and at least one of the following: IOP ≥ 21
mmHg, suspicious optic discs, or were on anti-glaucoma medications. Patients
were diagnosed with POAG if they had suspicious optic discs, open iridocorneal angles
confirmed by gonioscopy, and VF defects characteristic of glaucoma. Suspicious
optic discs were defined as noticeable cupping, neuroretinal rim thinning or
notching, or an RNFL defect characteristic of glaucoma1. Patients
with POAG were separated into mild, moderate, or severe based on their VF mean
deviation (MD) of >-6 dB, between -6 dB and -12 dB, and < -12 dB,
respectively, using the modified Hodapp-Parrish-Anderson classification(7).
Data Collection
Systemic patient data collected
included: age, ethnicity, gender, diagnosis of systemic hypertension, diabetes,
or cataracts, family history of glaucoma, and body mass index (BMI). Ocular
measurements collected included: best corrected visual acuity as LogMAR units
(BCVA), spherical equivalent, central corneal thickness (CCT) (Cornea-Gage Plus
Sonogage Pachymeter; Sonogage, Inc., Cleveland, OH), IOP measured by Goldmann
Applanation Tonometer (Haag-Streit, Inc., Koeniz, Switzerland), VF MD and
pattern standard deviation (PSD) measured by Humphrey Field Analyzer 3 and
analyzed with the Humphrey 24-2 Swedish Interactive Threshold Algorithm
(Humphrey Instruments, CA, USA), cup/disc ratio (C/D), previous ocular
surgeries, previous laser trabeculoplasties, number of anti-glaucoma
medications, and use of systemic carbonic anhydrase medications.
OCT-A operators were blinded to the
patient’s glaucoma diagnosis. OCT-A data was exported with Optovue RTVue XR
version 2016.2.0.35 (Avanti Widefield OCT with AngioVue OCT Angiography;
Optovue, Inc., Fremont, CA). The device uses an 840-nm diode laser source and
has a scanning rate of 70,000 A-scans per second(8). The software provides vascular
data at various retinal layers with an en face angiogram and a quantitative
representation of vessel density(9). The device shows the eye’s
vessel distribution by using split-spectrum amplitude-decorrelation to compare
the decorrelation signal, based on the differences in backscattered OCT signal
intensity(10). By taking multiple A-scans, the
scans are compiled into B-scans, which allow cross-sectional structural
information(11). Optic disc vessel density measurement is made by
using 3mm x 3mm field of view images centered on the ONH and focusing on the
segment from the internal limiting membrane to the posterior boundary of RNFL.
Macular vessel density is obtained with a 3mm x 3mm field of view images
centered on the macula homing in on the inner limiting membrane to the inner
plexiform layer. The peripapillary and parafovea vessel densities were
calculated with a 750 μm elliptical margin from the optic disc and an annular
margin with an inner diameter of 1 mm and an outer diameter of 2.5 mm from the
fovea, respectively(9). Examples of a moderate POAG
patient’s vessel density en face images are seen in Figure 1.
Figure 1: OCT-A and VF
images of a patient diagnosed with moderate POAG.
Figure
1:
Top row: Optic nerve head en face
angiograph with corresponding pattern standard deviation.
Bottom row: Macular en face angiograph
with mGCC map
OCT-A scanning parameters exported were:
foveal avascular zone (FAZ) area (mm2), disc area (mm2),
C/D, horizontal C/D, vertical C/D, cup area (mm2), rim area (mm2),
rim volume (mm3), nerve head volume (mm3), cup volume (mm3),
RNFL SSI, RNFL thickness (µm) (average, superior, inferior, temporal, nasal, superior
nasal, superior temporal, inferior nasal, and inferior temporal), mGCC SSI,
mGCC thickness (µm) (inner retina, superior, inferior), mGCC focal loss volume
(FLV) (%) and global loss volume (GLV) (%), ONH vessel density (%) (SSI, whole
image, inside disc, peripapillary, nasal, temporal, superior temporal, superior
nasal, inferior temporal, and inferior nasal), and macular vessel density (%)
(SSI, whole image, fovea, parafovea, superior, inferior, temporal, and nasal).
GLV and FLV are pattern analyses of the mGCC thickness map provided by Optovue(12). GLV represents an average amount
of mGCC loss across the entire eye and has the same concept as mean deviation
of VF, while FLV represents focal mGCC loss after correcting for the general
depression in the mGCC thickness topography map and has the same concept as
pattern standard deviation of VF(12).
Statistical
Analyses
Statistical analyses of data were performed
with IBM SPSS Statistics (IBM SPSS, Inc., New York, NY). One eye was randomly
selected per patient through the Microsoft Excel random number function. A
chi-square test was used to compare differences between groups of categorical
data and Jonckheere-Terpstra trend test and independent samples t-tests were
used to compare differences among groups for continuous data. Inter-patient
coefficients of variations (CV) were computed to evaluate the relative
variability among structural or vessel properties for determining glaucoma
stage. The CV is a measure of standard deviation that is normalized to the mean
for assessing precision. Multivariable linear regression was used to determine
the relationship between VF MD as the dependent variable and the whole image
macular vessel density, whole image optic disc vessel density, average RNFL,
and average mGCC as the independent variables while controlling for potential
confounders, such as age, BMI, gender, ethnicity, family history of glaucoma,
presence of hypertension, diabetes, or cataracts, BCVA, and SSI. An alpha level
of 0.05 was the cutoff for statistical significance.
RESULTS
Baseline
Characteristics
From 383 patients who fit the inclusion
criteria, 187 patients (48.8%) were excluded based on our exclusion criteria.
Patients were divided into 5 separate groups: 69 healthy controls (patients
without glaucoma), 36 patients with ocular hypertension, and 91 with POAG (54
mild, 25 moderate, and 12 severe). Demographic characteristics, structural
properties, and vessel densities of healthy control, ocular hypertension and
glaucomatous eyes are shown in Table I, Table II, and Table III, respectively.
Table I: Demographic
characteristics of healthy controls, ocular hypertension, and glaucomatous eyes
Variables
|
|
Controls (n=69) (%)
|
Ocular Hypertension
(n=36) (%)
|
Mild Glaucoma (n=54)
(%)
|
Moderate Glaucoma
(n=25) (%)
|
Severe Glaucoma
(n=12) (%)
|
P value*-all groups
|
P value**-controls
and ocular hypertension
|
P value ‡ -ocular hypertension and POAG
|
Age (years)
|
|
60.52±11.67
|
64.42±10.05
|
69.19±9.32
|
69.16±11.12
|
67.08±11.28
|
<0.01
|
0.09
|
0.14
|
BMI (kg/m²)
|
|
28.83±5.55
|
28.58±7.52
|
27.89±6.1
|
28.3±7.13
|
30.04±6
|
0.84
|
0.85
|
0.79
|
Gender
|
Male
|
24 (34.8)
|
11 (30.6)
|
22 (40.7)
|
17 (68)
|
1 (8.3)
|
<0.01
|
0.66
|
<0.01
|
Female
|
45 (65.2)
|
25 (69.4)
|
32 (59.3)
|
8 (32)
|
11 (91.7)
|
|
|
|
Ethnicity
|
White
|
30 (43.5)
|
22 (61.1)
|
27 (50)
|
9 (36)
|
8 (66.7)
|
0.35
|
0.25
|
0.29
|
Black
|
18 (26.1)
|
9 (25)
|
17 (31.5)
|
7 (28)
|
1 (8.3)
|
|
|
|
Hispanic
|
8 (11.6)
|
2 (5.6)
|
4 (7.4)
|
6 (24)
|
1 (8.3)
|
|
|
|
Others
|
13 (18.8)
|
3 (8.3)
|
6 (11.1)
|
3 (12)
|
2 (16.7)
|
|
|
|
Family History of
Glaucoma
|
Yes
|
33 (47.8)
|
22 (61.1)
|
28 (51.9)
|
6 (24)
|
4 (33.3)
|
0.12
|
0.16
|
0.12
|
No
|
32 (46.4)
|
10 (27.8)
|
21 (38.9)
|
14 (56)
|
6 (50)
|
|
|
|
Unknown
|
4 (5.8)
|
4 (11.1)
|
5 (9.3)
|
5 (20)
|
2 (16.7)
|
|
|
|
Hypertension
|
No
|
35 (50.7)
|
18 (50)
|
18 (33.3)
|
5 (20)
|
6 (50)
|
0.04
|
0.94
|
0.08
|
Yes
|
34 (49.3)
|
18 (50)
|
36 (66.7)
|
20 (80)
|
6 (50)
|
|
|
|
Diabetes
|
No
|
53 (76.8)
|
28 (77.8)
|
42 (77.8)
|
14 (56)
|
8 (66.7)
|
0.24
|
0.91
|
0.18
|
Yes
|
16 (23.2)
|
8 (22.2)
|
12 (22.2)
|
11 (44)
|
4 (33.3)
|
|
|
|
Hyperopia
|
No
|
33 (48.5)
|
12 (33.3)
|
26 (48.1)
|
9 (36)
|
4 (33.3)
|
0.13
|
0.43
|
0.08
|
Mild (<= -2D)
|
13 (19.1)
|
9 (25.0)
|
2 (3.7)
|
7 (28)
|
5 (41.7)
|
|
|
|
Moderate (-2D- -3D)
|
2 (2.9)
|
1 (2.8)
|
3 (5.6)
|
0
|
0
|
|
|
|
Severe (>=-3D)
|
0
|
1 (2.8)
|
0
|
0
|
0
|
|
|
|
Unknown
|
20 (29.4)
|
13 (36.1)
|
23 (42.6)
|
9 (36)
|
3 (25)
|
|
|
|
Myopia
|
No
|
16 (23.5)
|
12 (33.3)
|
8 (14.8)
|
8 (32)
|
6 (50)
|
0.36
|
0.16
|
0.30
|
Mild (<= -2D)
|
22 (32.4)
|
5 (13.9)
|
18 (33.3)
|
8 (32)
|
2 (16.7)
|
|
|
|
Moderate (-2D- -3D)
|
3 (4.4)
|
3 (8.3)
|
3 (5.6)
|
0
|
1 (8.3)
|
|
|
|
Severe (>=-3D)
|
6 (8.8)
|
1 (2.8)
|
3 (5.6)
|
1 (4)
|
0
|
|
|
|
Unknown
|
21 (30.9)
|
15 (41.7)
|
22 (40.7)
|
8 (32)
|
3 (25)
|
|
|
|
Best Corrected Visual
Acuity (LogMAR)
|
0
|
46 (66.7)
|
26 (72.2)
|
36 (66.7)
|
9 (36)
|
6 (50)
|
0.03
|
0.95
|
0.02
|
0.1
|
16 (23.2)
|
7 (19.4)
|
14 (25.9)
|
9 (36)
|
2 (16.7)
|
|
|
|
0.2
|
5 (7.2)
|
2 (5.6)
|
4 (7.4)
|
6 (24)
|
2 (16.7)
|
|
|
|
0.3
|
2 (2.9)
|
1 (2.8)
|
0
|
1 (4)
|
2 (16.7)
|
|
|
|
Cataract Status
|
None
|
19 (27.5)
|
5 (13.9)
|
9 (16.7)
|
3 (12)
|
1 (8.3)
|
<0.01
|
0.14
|
0.13
|
1+
|
36 (52.2)
|
20 (55.6)
|
19 (35.2)
|
9 (36)
|
5 (41.7)
|
|
|
|
2+
|
8 (11.6)
|
3 (8.3)
|
8 (14.8)
|
1 (4)
|
0
|
|
|
|
3+
|
0
|
0
|
0
|
2 (8)
|
0
|
|
|
|
Pseudophakia
|
6 (8.7)
|
8 (22.2)
|
18 (33.3)
|
10 (40)
|
6 (50)
|
|
|
|
Past Ocular Surgery
|
No
|
65 (94.2)
|
34 (94.4)
|
43 (79.6)
|
21 (84)
|
8 (66.7)
|
0.02
|
0.96
|
0.10
|
Yes
|
4 (5.8)
|
2 (5.6)
|
11 (20.4)
|
4 (16)
|
4 (33.3)
|
|
|
|
Past Laser
Trabeculoplasty
|
No
|
69 (100)
|
31 (86.1)
|
51 (94.4)
|
21 (84)
|
10 (83.3)
|
0.04
|
<0.01
|
0.40
|
Yes
|
0
|
5 (13.9)
|
3 (5.6)
|
4 (16)
|
2 (16.7)
|
|
|
|
Number of Ocular
Medications
|
0
|
69 (100)
|
3 (8.3)
|
0
|
4 (16)
|
1 (8.3)
|
<0.01
|
<0.01
|
<0.01
|
1
|
0
|
27 (75)
|
34 (63)
|
14 (56)
|
5 (41.7)
|
|
|
|
2
|
0
|
6 (16.7)
|
18 (33.3)
|
3 (12)
|
2 (16.7)
|
|
|
|
3
|
0
|
0
|
2 (3.7)
|
4 (16)
|
3 (25)
|
|
|
|
5
|
0
|
0
|
0
|
0
|
1 (8.3)
|
|
|
|
Systemic
Carbonic Anhydrase
Inhibitor
|
No
|
69 (100)
|
36 (100)
|
52 (96.3)
|
25 (100)
|
10 (83.3)
|
<0.01
|
1.00
|
0.03
|
Yes
|
0
|
0
|
2 (3.7)
|
0
|
2 (16.7)
|
|
|
|
IOP (mm Hg)
|
|
14.94±2.75
|
15.94±4.64
|
15.04±3.87
|
14.76±4.31
|
13.88±4.4
|
0.50
|
0.17
|
0.46
|
CCT (μm)
|
|
536.13±36.44
|
563.97±35.90
|
546.94±32.26
|
525.29±33.23
|
548.1±67.89
|
<0.01
|
<0.01
|
<0.01
|
Visual Field
|
Mean Deviation
|
-1.16±1.50
|
-0.80±1.51
|
-2.29±2.01
|
-8.26±1.51
|
-18.69±4.38
|
<0.01
|
0.24
|
<0.01
|
|
Pattern Standard
Deviation
|
1.91±0.74
|
1.88±0.97
|
2.96±1.84
|
6.9±3.15
|
11.35±3.31
|
<0.01
|
0.86
|
<0.01
|
Baseline
clinical data of patient eye per group reported as mean ± standard deviation.
P-values
from independent t-test and Jonckheere-Terpstra trend for continuous data and
chi-square for categorical data
*P-values
for all groups
**P-values
between controls and patients with ocular hypertension
‡
P-values between patients with ocular hypertension and POAG (mild, moderate,
and severe)
Table II: Structural
properties of healthy controls, ocular hypertension, and glaucomatous eyes
Variables
|
Controls (n=69) (%)
|
Ocular Hypertension
(n=36) (%)
|
Mild Glaucoma (n=54)
(%)
|
Moderate Glaucoma
(n=25) (%)
|
Severe Glaucoma
(n=12) (%)
|
P value*-all groups
|
P value**-controls
and ocular hypertension
|
P value ‡ -ocular hypertension and POAG
|
FAZ Area (mm²)
|
0.34±0.14
|
0.34±0.12
|
0.33±0.14
|
0.4±0.16
|
0.36±0.16
|
0.51
|
0.95
|
0.39
|
Avg SSI RNFL
|
57.91±12.43
|
57.07±11.98
|
55.6±8.58
|
49.62±12.06
|
51.55±9.68
|
0.02
|
0.75
|
0.03
|
Optic Disc Area
(mm²)
|
2.39±0.45
|
2.03±0.39
|
2.26±0.53
|
2.17±0.55
|
1.93±0.69
|
<0.01
|
<0.01
|
0.09
|
C/D ratio
|
0.49±0.14
|
0.43±0.17
|
0.54±0.15
|
0.57±0.17
|
0.73±0.12
|
<0.01
|
0.05
|
<0.01
|
Horizontal C/D ratio
|
0.77±0.14
|
0.68±0.2
|
0.78±0.14
|
0.81±0.13
|
0.9±0.1
|
<0.01
|
0.01
|
<0.01
|
Vertical C/D ratio
|
0.66±0.13
|
0.62±0.17
|
0.73±0.13
|
0.76±0.14
|
0.85±0.11
|
<0.01
|
0.15
|
<0.01
|
Optic Cup Area (mm²)
|
1.21±0.46
|
0.91±0.49
|
1.25±0.47
|
1.24±0.47
|
1.4±0.48
|
<0.01
|
0
|
<0.01
|
Optic Rim Area (mm²)
|
1.18±0.28
|
1.11±0.29
|
1.01±0.34
|
0.93±0.39
|
0.53±0.35
|
<0.01
|
0.26
|
<0.01
|
Optic Rim Volume
(mm³)
|
0.1±0.05
|
0.1±0.05
|
0.07±0.05
|
0.06±0.05
|
0.02±0.02
|
<0.01
|
0.93
|
<0.01
|
Nerve Head Volume
(mm³)
|
0.2±0.1
|
0.21±0.1
|
0.15±0.08
|
0.14±0.09
|
0.05±0.05
|
<0.01
|
0.98
|
<0.01
|
Cup Volume (mm³)
|
0.43±0.27
|
0.3±0.31
|
0.4±0.27
|
0.36±0.29
|
0.47±0.27
|
0.21
|
0.03
|
0.27
|
Average RNFL (μm)
|
96.11±9.8
|
92±10.02
|
82.95±11.75
|
76.91±14.45
|
60.13±7.51
|
<0.01
|
0.05
|
<0.01
|
Superior RNFL (μm)
|
97.78±10.81
|
94.54±10.76
|
85.1±12.51
|
79.58±13.79
|
61.27±10.71
|
<0.01
|
0.16
|
<0.01
|
Inferior RNFL (μm)
|
94.45±10.32
|
89.47±10.41
|
80.8±12.71
|
74.24±16.29
|
58.99±7.28
|
<0.01
|
0.02
|
<0.01
|
Temporal RNFL (μm)
|
71.15±9.52
|
70.08±11.26
|
63.4±9.45
|
59.49±11.18
|
50.3±11
|
<0.01
|
0.61
|
<0.01
|
Nasal RNFL (μm)
|
74.69±11.07
|
73.32±11.67
|
68.27±11.86
|
62.74±12.01
|
54.58±12.28
|
<0.01
|
0.56
|
<0.01
|
RNFL Superior
Temporal (μm)
|
127.73±15.6
|
123.37±19.67
|
107.8±17.38
|
100.68±19.7
|
71.57±19.16
|
<0.01
|
0.23
|
<0.01
|
RNFL Superior Nasal
(μm)
|
106.63±18.59
|
100.63±17.2
|
92.79±19.5
|
87.97±19.21
|
66.46±13.76
|
<0.01
|
0.12
|
<0.01
|
RNFL Inferior Nasal
(μm)
|
108.71±18.52
|
102.02±16.76
|
93.51±19.05
|
87.64±24.28
|
66.29±14.12
|
<0.01
|
0.08
|
<0.01
|
RNFL Inferior
Temporal (μm)
|
134.12±17.8
|
123.18±19.67
|
106.18±23.03
|
94.52±29.81
|
66.95±12.42
|
<0.01
|
0.01
|
<0.01
|
Avg SSI Ganglion
Cell Complex
|
65.15±9.44
|
63.27±10.34
|
62.11±6.83
|
59.81±7.76
|
57.35±8.5
|
0.01
|
0.36
|
0.12
|
mGCC Average (μm)
|
94.29±9.65
|
90.23±7.75
|
83.71±8.65
|
80.31±14.99
|
67.92±10.9
|
<0.01
|
0.04
|
<0.01
|
mGCC Superior
Average (μm)
|
93.56±10.4
|
90.44±7.32
|
84.65±9.21
|
82.12±13.79
|
67.89±11.14
|
<0.01
|
0.12
|
<0.01
|
mGCC Inferior
Average (μm)
|
95.04±9.37
|
90.04±8.8
|
82.77±10.05
|
78.52±17.08
|
67.98±13.35
|
<0.01
|
0.01
|
<0.01
|
mGCC-Focal Loss
Volume (%)
|
1.08±1.21
|
1.7±2.43
|
2.93±3.46
|
6.12±3.92
|
9.39±4.03
|
<0.01
|
0.09
|
<0.01
|
mGCC-Global Loss
Volume (%)
|
4.53±4.78
|
6.83±5.8
|
12.37±7.82
|
17.05±11.31
|
29.39±8.89
|
<0.01
|
0.04
|
<0.01
|
mGCC-Root Mean
Square
|
0.07±0.05
|
0.08±0.04
|
0.09±0.05
|
0.14±0.05
|
0.17±0.06
|
<0.01
|
0.51
|
<0.01
|
Baseline
clinical data of patient eye per group reported as mean ± standard deviation.
P-values
from independent t-test and Jonckheere-Terpstra trend for continuous data and
chi-square for categorical data
*P-values
for all groups
**P-values
between controls and patients with ocular hypertension
‡
P-values between patients with ocular hypertension and POAG (mild, moderate,
and severe)
Table III: Vessel
Ddensities of healthy controls, ocular hypertension, and glaucomatous eyes
Variables
|
Controls (n=69) (%)
|
Ocular Hypertension (n=36)
(%)
|
Mild Glaucoma (n=54)
(%)
|
Moderate Glaucoma
(n=25) (%)
|
Severe Glaucoma
(n=12) (%)
|
P value*-all groups
|
P value**-controls
and ocular hypertension
|
P value ‡ -ocular hypertension and POAG
|
Avg SSI Disc
|
60.42±11.81
|
59.6±11.74
|
56.77±9.78
|
52.33±8.83
|
49±10.83
|
<0.01
|
0.74
|
<0.01
|
Whole Image ONH
Vessel Density (%)
|
56.71±4.36
|
56.79±5.08
|
52.85±5.15
|
49.82±4.06
|
43.12±4.19
|
<0.01
|
0.94
|
<0.01
|
Inside Disc Vessel
Density (%)
|
50.27±6.51
|
50.92±6.98
|
47.91±6.64
|
46.13±6.63
|
43.53±5.14
|
<0.01
|
0.65
|
<0.01
|
Peripapillary Vessel
Density (%)
|
61.32±4.35
|
61.37±5.35
|
57.06±6.7
|
53.43±4.99
|
47.01±3.47
|
<0.01
|
0.96
|
<0.01
|
Nasal Vessel Density
(%)
|
59.53±4.89
|
59.76±6.29
|
55.46±7.98
|
52.84±6.94
|
47.41±5.38
|
<0.01
|
0.84
|
<0.01
|
Inferior Nasal
Vessel Density (%)
|
62.97±6.84
|
62.66±5.71
|
59.04±9.8
|
57.11±9.52
|
53.17±6.66
|
<0.01
|
0.82
|
0.01
|
Inferior Temporal
Vessel Density (%)
|
66.13±4.35
|
64.52±8.21
|
60.02±9.07
|
54.32±10.65
|
45.58±9.89
|
<0.01
|
0.2
|
<0.01
|
Superior Temporal
Vessel Density (%)
|
63.71±5.85
|
64.72±8.46
|
59.97±7.82
|
51.91±10.66
|
43.94±9.62
|
<0.01
|
0.49
|
<0.01
|
Superior Nasal
Vessel Density (%)
|
61.29±6.02
|
59.16±7.91
|
56.56±9.43
|
55.14±7.05
|
43.45±7.74
|
<0.01
|
0.14
|
<0.01
|
Temporal Vessel
Density (%)
|
59.29±6.62
|
60.64±7.3
|
55.56±7.68
|
52.22±5.22
|
47.21±7.3
|
<0.01
|
0.35
|
<0.01
|
Avg SSI Macular
|
65.83±7.49
|
62.79±11.7
|
63.13±7.74
|
59.01±8.28
|
57.24±7.47
|
0.01
|
0.18
|
0.18
|
Whole Image Macular
Vessel Density (%)
|
50.27±4.23
|
49.04±4.7
|
48.12±3.8
|
46.13±3.91
|
43.43±4.71
|
<0.01
|
0.26
|
<0.01
|
Fovea Vessel Density
(%)
|
27.01±5.42
|
26.76±5.96
|
27.69±5.67
|
24.52±6.05
|
27.84±8.4
|
0.38
|
0.86
|
0.28
|
Parafovea Vessel
Density (%)
|
52.72±4.66
|
51.4±5.28
|
50.74±4.04
|
48.45±3.98
|
45.77±4.98
|
<0.01
|
0.27
|
<0.01
|
Superior-Hemi Vessel
Density (%)
|
52.84±4.96
|
51.74±5.09
|
51.22±4.13
|
49±3.64
|
46.88±4.33
|
<0.01
|
0.37
|
0.01
|
Inferior-Hemi Vessel
Density (%)
|
52.61±4.62
|
51.06±6.01
|
50.27±4.34
|
47.9±4.74
|
44.69±6.09
|
<0.01
|
0.22
|
<0.01
|
Temporal Vessel
Density (%)
|
52.61±3.7
|
51.15±5.35
|
50.57±3.61
|
48.53±3.76
|
46.1±5.44
|
<0.01
|
0.17
|
0.01
|
Nasal Vessel Density
(%)
|
51.95±5.16
|
50.38±6
|
50.74±4.36
|
47.07±5.28
|
46.25±5.01
|
<0.01
|
0.24
|
0.02
|
Baseline
clinical data of patient eye per group reported as mean ± standard deviation.
P-values
from independent t-test and Jonckheere-Terpstra trend for continuous data and
chi-square for categorical data
*P-values
for all groups
**P-values
between controls and patients with ocular hypertension
‡
P-values between patients with ocular hypertension and POAG (mild, moderate,
and severe)
There was no statistically
significant difference among the groups in terms of BMI, family history of
glaucoma, IOP, ethnicity, and self-reported history of diabetes. The groups
differed by age, gender, self-reported history of hypertension, CCT, VF MD and
PSD. Healthy controls had the youngest age. Patients with ocular hypertension
had the highest CCT. Our patient population was ethnically diverse. There were no significant differences in whole image ONH
vessel density and macular vessel density by race (p=0.96;0.07) or gender (p=0.78;0.18).
Controls and
Ocular hypertension
There was no
difference in SSI for all scan types. Compared to healthy controls, patients
with ocular hypertension had a significantly thicker CCT, and a smaller optic
disc area, horizontal C/D, optic cup area, and cup volume.
For structural properties, patients with ocular hypertension had significantly thinner average RNFL, inferior RNFL, inferior temporal RNFL, average mGCC, inferior mGCC, and a larger GLV. We found no changes in vessel density. The most
pronounced structural property change was an increase in GLV by 50.8% followed
by a decrease of 8.16% in inferior temporal RNFL thickness and a decrease of
5.27% in inferior RNFL thickness.
Table IV shows the CV of whole image ONH vessel
density, whole image macular vessel density, average RNFL thickness, and
average mGCC thickness. Structural properties had a higher CV compared to
vessel density.
All remaining
variables in Table I through Table III had no significant difference between
healthy controls and patients with ocular hypertension
Table IV:
Inter-patient Coefficients of Variation by group
|
Control (n=69)
|
Ocular Hypertension (n=36)
|
Mild Glaucoma (n=54)
|
Moderate Glaucoma (n=25)
|
Severe Glaucoma (n=12)
|
Average RNFL (μm)
|
10.20%
|
10.89%
|
14.16%
|
18.78%
|
12.48%
|
mGCC Average (μm)
|
10.23%
|
8.59%
|
10.34%
|
18.66%
|
16.05%
|
Whole Image Disc Vessel Density (%)
|
7.70%
|
8.94%
|
9.75%
|
8.15%
|
9.72%
|
Whole Image Macular Vessel Density (%)
|
8.42%
|
9.59%
|
7.89%
|
8.48%
|
10.85%
|
RNFL: Retinal
nerve fiber layer
mGCC: Macular
ganglion cell complex
Ocular
hypertension and POAG
There was a
significant decrease in SSI for RNFL and ONH vessel density scans between
patients with ocular hypertension and severe POAG. Whole image ONH vessel
density, whole image macular vessel density, average RNFL thickness, and
average mGCC thickness decreased as glaucoma progressed from ocular
hypertension to severe stage as shown in Table II, Table III, and Figure 2. The
most pronounced structural property or vessel density change was an increase in
FLV by 68.7% followed by an increase in GLV by 50.3% and a decrease in RNFL
superior temporal thickness by 7.22%.
As glaucoma
progressed from ocular hypertension to severe glaucoma, the CV for vessel
density measurements were smaller compared to structural property measurements.
The range of CV for both vessel densities were <3%,
while the range of CV
for both structural properties were >7.5Ethnicity, BMI,
family history of glaucoma, presence of hypertension, diabetes, or cataracts,
past ocular surgeries, past laser trabeculoplasties, IOP, CCT, FAZ area, optic
cup area, cup volume, and fovea vessel density had no significant difference
between groups.
Figure 2:
Boxplots for structural properties and vessel density by patient groups
Boxplots
represent average RNFL, mGCC average, whole image macular and ONH vessel
density by healthy controls, patients with ocular hypertension, and with POAG
(mild, moderate, and severe). The horizontal lines within the box represent the
medians. The boxes represent the interquartile range between the 1st
and 3rd quartile. The top whisker is the largest value within
1.5*the interquartile range from the 3rd quartile. The bottom
whisker is the smallest value within 1.5*the interquartile range from the 1st
quartile. Values outside these whiskers are defined as outliers and are
represented by circles.
RNFL: Retinal
nerve fiber layer
mGCC: Macular
ganglion cell complex
Predictors of
Glaucoma Progression
Table V summarizes the linear
relationship of VF MD on structural properties and vessel density. Multivariate
linear regression analysis showed that whole image ONH vessel density, whole
image macular vessel density, average RNFL thickness, average mGCC thickness,
and cataract status were predictive of worsening VF MD. The measured structural
properties and vessel density were equally effective at determining the
glaucoma stage.
Table V: Multivariate linear regression analyses for dependent
variable, Visual Field Mean Deviation
Independent Variable
|
Adjusted Beta coefficient* (95% CI)
|
Pearson's correlation, r
|
p
|
Average RNFL (μm)
|
0.20 (0.16, 0.24)
|
0.658
|
<0.001
|
mGCC Average (μm)
|
0.19 (0.14, 0.24)
|
0.591
|
<0.001
|
Whole Image Disc Vessel Density (%)
|
0.68 (0.52, 0.85)
|
0.627
|
<0.001
|
Whole Image Macular Vessel Density (%)
|
0.47 (0.25, 0.70)
|
0.487
|
<0.001
|
*Adjusted
for age, BMI, gender, ethnicity, family history of glaucoma, presence of
hypertension, diabetes, or cataracts, BCVA, and SSI.
CI:
confidence interval
RNFL:
Retinal nerve fiber layer
mGCC:
Macular ganglion cell complex
DISCUSSION
We evaluated structural
properties and vessel density between healthy controls, patients with ocular
hypertension, and with POAG (mild, moderate, and severe). In our patient
population, we found that vessel density and structural properties assessed by
OCT-A were equally effective at providing an objective measure of glaucoma
damage in the eye. In addition, we found structural property decreases from
healthy controls to patients with ocular hypertension but did not find vessel
density decreases. This could suggest that structural damage may occur before
vessel density damage in patients with ocular hypertension. These objective
measures of glaucomatous damage could signify an improvement over VF tests in
the diagnosis of glaucoma.
Controls and
Ocular hypertension
In our patient population, we found
differences in some structural properties between controls and patients with
ocular hypertension, but no changes in vessel density. The most pronounced
structural property change was in the RNFL inferior temporal sector. This
sector corresponds to the nasal step defect seen in early visual fields
abnormalities, which support that our patients with ocular hypertension have
early glaucomatous damage that can be detected through RNFL changes while
having normal visual fields(5,13,14).
Other
studies using OCT-A have investigated vessel density changes in patients with
ocular hypertension compared to healthy controls with conflicting results. Triolo et al.
noticed decreases in RNFL thickness and none in ONH or macular vessel density(15). In another study, Manalastas et
al. found significant RNFL thickness and ONH vessel density decreases, but none
for macular vessel density(6). Finally, Yarmohammadi et al.
found significant decreases for RNFL and whole image ONH vessel density, but no
changes for peripapillary vessel density(16). The consistency of RNFL thickness decreases with
variable vessel density decreases suggest that structural properties are
affected before vessel density in early glaucomatous damage. Another
possibility for the variable vessel densities between studies is that vessel
density damage might be hidden by large vessels early in glaucoma. Geyman et al
noted that removal of large vessels increased the accuracy of detecting mild
glaucoma(8). This could suggest that
increased IOP affects smaller vessels first and could account for the variable
vessel density change in patients with ocular hypertension as the large vessels
mask small vessel damage(8).
Ocular
hypertension and POAG
In our study, we noticed a decreasing,
stepwise trend in RNFL, mGCC, ONH and macular vessel density as glaucoma
progressed. From the similar Pearson’s coefficients, this suggests that
structural properties and vessel density are equally effective at measuring
glaucomatous damage. Our study results are like those found by Geyman et al.
and Chen et al. who also found that both structural properties and vessel
density are similarly effective at measuring glaucoma stage(8,17).
While
other studies have looked at CV in POAG using OCT-A to measure reproducibility
of OCT-A(18–20), these studies have only looked at healthy controls
or POAG patients overall. This study is unique because we looked at the CV
between patients and across all stages of POAG. We noticed that as glaucoma
progressed, the range of CV for structural properties is greater than for
vessel density. This suggests that as glaucoma progresses, vessel density might
have better reproducibility compared to structural properties. Therefore, for
more severe cases of POAG, vessel density might provide more consistent
measurements for clinical management and might be more effective for detecting
changes over time(21).
LIMITATION
One limitation in this study is that our
VF and OCT-A scans were not done close together. Therefore, patients could have
had progression of their glaucoma and they could have a discrepancy between
their VF and OCT-A scan. We attempted to mitigate this limitation by excluding
any patients whose glaucoma diagnosis changed in the interim. A second
limitation is that SSI has been shown to affect vessel density measurements(9). We attempted to mitigate this
by including SSI in our multivariate linear regressions. A third limitation is
that the Optovue RTVue XR software only supports 3mm x 3mm optic disc images
for testing purposes and is not representative of their release software. This
might cause some inaccuracies as images had lower resolution and the values
cannot be compared to later software versions or different image sizes. A
fourth limitation is that our
horizontal C/D and optic cup area was greater in healthy controls than
patients with ocular hypertension. This could represent a sampling bias as some
of our healthy controls were referred to our eye care clinic due to concerns
for glaucoma due to increased cup size. However, they were found to have no
evidence of glaucomatous damage after an eye exam.
CONCLUSION
ONH and macular vessel density and
structural properties assessed by OCT-A can provide an equally effective
objective measure of glaucoma damage in the eye. Our study has shown that
structural damage may occur before vessel density damage in ocular hypertension.
For more severe POAG, vessel density might have better reproducibility. More
longitudinal studies are needed to evaluate vessel density changes over the
development of POAG.
Acknowledgements
Supported in part by the Research to
Prevent Blindness, New York, NY; Visual Sciences Core Grant EY020799 and NIH
CTSA Grant UL1TR001105.
REFERENCES
1. Prum
Jr. BE, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, et
al. Primary Open-Angle Glaucoma Preferred Practice Pattern Guidelines.
Ophthalmology. 2016 Jan 1;123(1):P41–111.
2. Tanna AP, Bandi JR, Budenz DL,
Feuer WJ, Feldman RM, Herndon LW, et al. Interobserver agreement and
intraobserver reproducibility of the subjective determination of glaucomatous
visual field progression. Ophthalmology. 2011;118(1):60–5.
3. Liu JHK, Weinreb RN. Monitoring
intraocular pressure for 24 h. Br J Ophthalmol. 2011 May 1;95(5):599–600.
4. Kuang TM, Zhang C, Zangwill LM,
Weinreb RN, Medeiros FA. Estimating lead time gained by optical coherence
tomography in detecting glaucoma before development of visual field defects.
Ophthalmology. 2015 Apr 8;122(10):2002–9.
5. Chen TC, Hoguet A, Junk AK,
Nouri-Mahdavi K, Radhakrishnan S, Takusagawa HL, et al. Spectral-Domain
OCT: Helping the Clinician Diagnose Glaucoma: A Report by the American Academy
of Ophthalmology. Ophthalmology. 2018;125(11):1817–27.
6. Manalastas PIC, Zangwill LM, Daga
FB, Christopher MA, Saunders LJ, Shoji T, et al. The Association
between Macula and ONH Optical Coherence Tomography Angiography (OCT-A) Vessel
Densities in Glaucoma, Glaucoma Suspect, and Healthy Eyes. Vol. 27, Journal of
Glaucoma. 2018. 227–232 p.
7. Mills RP, Budenz DL, Lee PP,
Noecker RJ, Walt JG, Siegartel LR, et al. Categorizing the stage of
glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol. 2006 Mar
25;141(1):24–30.
8. Geyman LS, Garg RA, Suwan Y,
Trivedi V, Krawitz BD, Mo S, et al. Peripapillary perfused capillary density
in primary open - Angle glaucoma across disease stage: An optical coherence
tomography angiography study. Vol. 101, British Journal of Ophthalmology. 2017.
1261–1268 p.
9. Hou H, Moghimi S, Zangwill LM,
Shoji T, Ghahari E, Manalastas PIC, et al. Inter-eye Asymmetry of Optical
Coherence Tomography Angiography Vessel Density in Bilateral Glaucoma, Glaucoma
Suspect, and Healthy Eyes. Am J Ophthalmol. 2018;190:69–77.
10. Jia Y, Tan O, Tokayer J, Potsaid B,
Wang Y, Liu JJ, et al. Split-spectrum amplitude-decorrelation angiography
with optical coherence tomography. Opt Express. 2012 Feb 13;20(4):4710.
11. Spaide RF, Klancnik JM, Cooney MJ. Retinal vascular
layers in macular telangiectasia type 2 imaged by optical coherence tomographic
angiography. JAMA Ophthalmol. 2015 Jan 1;133(1):66–73.
12. Lisboa R, Paranhos A, Weinreb RN,
Zangwill LM, Leite MT, Medeiros FA. Comparison of different spectral domain
OCT scanning protocols for diagnosing preperimetric glaucoma. Vol. 54,
Investigative Ophthalmology and Visual Science. 2013. 3417–3425 p.
13. Hood DC. Improving our
understanding, and detection, of glaucomatous damage: An approach based upon optical
coherence tomography (OCT). Prog Retin Eye Res. 2016;57:1–30.
14. Baek SU, Kim KE, Kim YK, Park KH,
Jeoung JW. Development
of Topographic Scoring System for Identifying Glaucoma in Myopic Eyes: A
Spectral-Domain OCT Study. Ophthalmology. 2018;125(11):1710–9.
15. Triolo G, Rabiolo A, Shemonski ND,
Fard A, Di Matteo F, Sacconi R, et al. Optical coherence tomography angiography
macular and peripapillary vessel perfusion density in healthy subjects,
glaucoma suspects, and glaucoma patients. Investig Ophthalmol Vis Sci. 2017 Nov
6;58(13):5713–22.
16. Yarmohammadi A, Zangwill LM,
Diniz-Filho A, Suh MH, Yousefi S, Saunders LJ, et al. Relationship
between Optical Coherence Tomography Angiography Vessel Density and Severity of
Visual Field Loss in Glaucoma. Ophthalmology. 2016 Mar 23;123(12):2498–508.
17. Chen HSL, Liu CH, Wu WC, Tseng HJ,
Lee YS.
Optical coherence tomography angiography of the superficial microvasculature in
the macular and peripapillary areas in glaucomatous and healthy eyes. Investig
Ophthalmol Vis Sci. 2017 Jul 20;58(9):3637–45.
18. Manalastas PIC, Zangwill LM, Saunders
LJ, Mansouri K, Belghith A, Suh MH, et al. Reproducibility of optical
coherence tomography angiography macular and optic nerve head vascular density
in glaucoma and healthy eyes. J Glaucoma. 2017;26(10):851–9.
19. Holló G. Intrasession and
Between-Visit Variability of Sector Peripapillary Angioflow Vessel Density
Values Measured with the Angiovue Optical Coherence Tomograph in Different
Retinal Layers in Ocular Hypertension and Glaucoma. PLoS One. 2016 Aug
18;11(8):e0161631.
20. Liang Liu, MD, Yali Jia, PhD, Hana L. Takusagawa, MD,
Alex D. Pechauer, BS, Beth Edmunds, MD, PhD, Lorinna Lombardi, MD, Ellen Davis,
MD, John C. Morrison, MD, and David Huang, MD P. Optical Coherence Tomography
Angiography of the Peripapillary AMA Ophthalmol. JAMA Ophthalmol. 2015 Sep 1;133(9):1045–52.
21. Mwanza J-C, Chang RT, Budenz DL,
Durbin MK, Gendy MG, Shi W, et al. Reproducibility of Peripapillary Retinal
Nerve Fiber Layer Thickness and Optic Nerve Head Parameters Measured with
Cirrus HD-OCT in Glaucomatous Eyes. Invest Ophthalmol Vis Sci. 2010 Nov
1;51(11):5724–30.